Annals of Surgical Oncology最新文献

{"title":"Highlights and Perspectives from the Society of Surgical Oncology’s Statements on Bilateral and Contralateral Risk-Reducing Mastectomy","authors":"Shayna L. Showalter MD, Christine Laronga MD, Society of Surgical Oncology Breast Disease Site Work Group","doi":"10.1245/s10434-025-17279-9","DOIUrl":"10.1245/s10434-025-17279-9","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":"32 6","pages":"3857 - 3860"},"PeriodicalIF":3.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Visual Abstract: Risk Factors for Regrowth After Nonoperative Management for Rectal Cancer.","authors":"Neal Bhutiani, Kentaro Ochiai, Oliver Peacock, Y Nancy You, Brian K Bednarski, Craig Messick, John M Skibber, Michael G White, George J Chang, Tsuyoshi Konishi, Abhineet Uppal","doi":"10.1245/s10434-025-17057-7","DOIUrl":"https://doi.org/10.1245/s10434-025-17057-7","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of Surgical Axillary Staging in Microinvasive Ductal Carcinoma In Situ: A National Cancer Database Analysis","authors":"Christian X. Lava MS,&nbsp;Varsha Harish BS,&nbsp;Kelly Kapp MD,&nbsp;Karen R. Li BBA,&nbsp;Austin D. Williams MD, MSEd,&nbsp;Nathan Wong MD,&nbsp;Sami Ferdousian MS,&nbsp;Carmen De Carvajal BS,&nbsp;Ashwini Paranjpe MD,&nbsp;Ian T. Greenwalt MD,&nbsp;Jennifer D. Son MD,&nbsp;Kenneth L. Fan MD,&nbsp;Lucy M. De La Cruz MD","doi":"10.1245/s10434-024-16727-2","DOIUrl":"10.1245/s10434-024-16727-2","url":null,"abstract":"<div><h3>Background</h3><p>Surgical axillary staging (ASx) of patients with microinvasive ductal carcinoma <i>in situ</i> (cT1mi) is debated due to the low occurrence of nodal metastasis. This study aimed to assess the utility of surgical axillary staging for clinically node-negative (cN0) T1mi breast cancer patients.</p><h3>Methods</h3><p>This retrospective cohort study analyzed data from the National Cancer Database (NCDB) to investigate the axillary status of patients with cT1mi breast cancer between 2012 and 2019. Patient demographics, clinical characteristics, treatment methods, and pathologic findings were collected.</p><h3>Results</h3><p>Of 10,843 patients, 9220 (85%) underwent ASx, whereas 1623 (15%) did not. Of the 4190 patients who underwent mastectomy, 244 (6%) did not undergo ASx, whereas 3946 (94%) did, 373 (9%) of whom were pN+. Of the 9069 patients who underwent ASx and had known nodal status, 8512 (94%) were pN– and 557 (6%) were pN+. The factors independently associated with increased odds of having positive nodes were younger age (odds ratio [OR], 1.02; 95% confidence interval [CI], 1.01–1.03; <i>p &lt;</i> 0.001), black race (OR, 1.51; 95% CI, 1.12–2.10; <i>p</i> = 0.007), lymphovascular invasion (OR, 13.72; 95% CI, 10.25–18.36; <i>p</i> &lt; 0.001), and mastectomy (OR, 1.98; 95% CI, 1.57–2.51; <i>p</i> &lt; 0.001). Among the pN+ patients, only 64 (1%) had ≥3 positive nodes and would require axillary lymph node dissection (ALND).</p><h3>Conclusion</h3><p>Surgical axillary staging is commonly performed for patients with cT1mi breast cancer despite the pN– status of most and the disproportionate morbidity associated with ASx. Identifying factors that predict a higher likelihood of pN+ status could allow for personalized surgical approaches, reducing unnecessary ASx for many patients.</p></div>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":"32 6","pages":"4023 - 4033"},"PeriodicalIF":3.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143902750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: ASO Author Reflections: Artificial Intelligence-Augmented Detection of Bladder Tumors.","authors":"Zixing Ye, Yingjie Li, Zhigang Ji","doi":"10.1245/s10434-025-17192-1","DOIUrl":"https://doi.org/10.1245/s10434-025-17192-1","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Hopes for Retroperitoneal-First Laparoscopic Approach-Assisted Lymph Node Dissection for Incidental Gallbladder Cancer.","authors":"Takuma Karasuyama, Gozo Kiguchi, Osamu Takeyama","doi":"10.1245/s10434-025-17261-5","DOIUrl":"https://doi.org/10.1245/s10434-025-17261-5","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Anastomotic Leaks on Long-Term Survival in Patients with Esophageal Squamous Cell Carcinoma Following McKeown Esophagectomy: A Propensity Score-Matched Analysis.","authors":"Chufeng Zeng, Xu Zhang, Bei Jia, Yi Hu, Peng Lin, Jianhua Fu, Hao Long, Tiehua Rong, Xiaodong Su","doi":"10.1245/s10434-025-17206-y","DOIUrl":"https://doi.org/10.1245/s10434-025-17206-y","url":null,"abstract":"<p><strong>Background: </strong>The impact of anastomotic leak (AL) on the long-term survival of patients with esophageal squamous cell carcinoma (ESCC) remains unclear. This study investigated whether AL influences the long-term survival of patients with ESCC following McKeown esophagectomy.</p><p><strong>Patients and methods: </strong>An original database was queried to identify patients with ESCC who underwent McKeown esophagectomy between 2012 and 2020 at a high-volume cancer center. Overall survival (OS) and disease-free survival (DFS) were compared using Kaplan-Meier (KM) curves. Cox regression analysis was used for multivariate analysis. Propensity score matching (PSM) was used to adjust for the confounding factors.</p><p><strong>Results: </strong>A total of 1614 patients were included, of whom 16.9% developed AL. In patients without neoadjuvant therapy, for patients with and without AL, the 5-year OS was 55.8% and 62.0%, and the 5-year DFS was 48.7% and 59.1%, respectively (OS: p = 0.37, DFS: p = 0.046). In the neoadjuvant cohort, for patients with and without AL, the 5-year OS was 57.9% and 63.2%, and the 5-year DFS was 55.4% and 58.8%, respectively (OS: p = 0.48, DFS: p = 0.78). Moreover, AL significantly increased the risk of distant recurrence in patients without neoadjuvant therapy (p = 0.023).</p><p><strong>Conclusions: </strong>These findings suggest that AL negatively influences DFS in patients without neoadjuvant therapy, but does not significantly affect long-term survival in patients receiving neoadjuvant treatment. Intensive treatment and follow-up plan should be considered when patients without neoadjuvant therapy.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conditional Relative Survival of Gallbladder Cancer: A Population-Based Study in a High-Incidence Asian Country from 1999 to 2021.","authors":"Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han","doi":"10.1245/s10434-025-17237-5","DOIUrl":"https://doi.org/10.1245/s10434-025-17237-5","url":null,"abstract":"<p><strong>Background: </strong>Dynamic prognostic information is important for treatment decisions and consultations among patients with gallbladder cancer (GBC), given its poor prognosis, especially in the advanced stage. We aimed to investigate long-term conditional relative survival (CS) rates in patients with GBC in Korea, which has a notably high incidence of GBC.</p><p><strong>Methods: </strong>Data regarding 40,774 individuals diagnosed with GBC between 1999 and 2021 were obtained from the Korea Central Cancer Registry. CS was analyzed across strata, including stage as well as the first course of treatment.</p><p><strong>Results: </strong>The overall 5-year relative survival rate at diagnosis, 3-year CS of 2-year survivors (the probability of surviving another 3 years among 2-year survivors), and 5-year CS of 5-year survivors were 29.9, 79.3, and 91.1%, respectively. Postoperatively, 94.4% (localized stage) and 76.5% (regional stage) of 2-year survivors survived for an additional 3 years. Moreover, 95.4% (localized stage) and 89.4% (regional stage) of 5-year survivors survived for an additional 5 years. The conditional probability of death within the first year after diagnosis increased gradually across age groups among overall patients, with the lowest (33.8%) and highest (67.7%) probabilities being in the 20-39 and ≥ 80 years age groups, respectively.</p><p><strong>Conclusions: </strong>Greater than 75% of patients with regional-stage GBC who survive the initial 2 postoperative years survive for an additional 3 years. Unlike patients with regional-stage GBC, whose 5-year survival rates continue to decrease among 5-year survivors, patients with localized-stage GBC may not require follow-up beyond 5 postoperative years since their survival probability after 5 years exceeds 95%.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.","authors":"Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, Junsung Choi, David J Eschelman, Evan S Glazer, Aslam Ejaz, J Harrison Howard, Erika Richtig, Sebastian Ochsenreither, Sunil A Reddy, Michael C Lowe, Georgia M Beasley, Anja Gesierich, Armin Bender, Martin Gschnell, Reinhard Dummer, Michel Rivoire, Ana Arance, Stephen William Fenwick, Joseph J Sacco, Sebastian Haferkamp, Carsten Weishaupt, Johnny John, Matthew Wheater, Christian H Ottensmeier","doi":"10.1245/s10434-025-17231-x","DOIUrl":"https://doi.org/10.1245/s10434-025-17231-x","url":null,"abstract":"<p><strong>Background: </strong>Metastatic uveal melanoma (mUM) has a poor prognosis, with liver metastases typically presenting a therapeutic challenge. Melphalan/Hepatic Delivery System (Melphalan/HDS) is a drug/medical device combination used for liver-directed treatment of unresectable mUM patients. This study assessed efficacy and safety of Melphalan/HDS versus best alternative care (BAC).</p><p><strong>Methods: </strong>Eligible patients with unresectable mUM were randomized (1:1) to receive Melphalan/HDS (3 mg/kg ideal body weight) once every 6 to 8 weeks for a maximum of 6 cycles or BAC. Due to slow enrollment and patient reluctance to receive BAC treatment, the study design was amended to a single-arm Melphalan/HDS study, and all efficacy analyses of the randomized study were treated as exploratory.</p><p><strong>Results: </strong>The study enrolled 85 patients. Eligible patients were randomized to receive Melphalan/HDS (n = 43) or BAC (n = 42), and 72 patients received study treatment (Melphalan/HDS [n = 40]; BAC [n = 32]). Exploratory analyses of efficacy endpoints showed numerical differences consistently favoring the Melphalan/HDS arm versus BAC (median overall survival: 18.5 vs. 14.5 months; median progression-free survival: 9.1 vs. 3.3 months; objective response rate: 27.5% vs. 9.4%; and disease control rate: 80.0% vs. 46.9%). Serious adverse events (SAEs) occurred in 51.2% of Melphalan/HDS and in 21.9% of BAC patients. The most common (>5%) SAEs included thrombocytopenia (19.5%), neutropenia (9.8%), leukopenia (9.8%) and febrile neutropenia (7.3%) in Melphalan/HDS patients and cholecystitis, nausea and vomiting (6.3% each) in BAC patients. No treatment-related deaths were observed.</p><p><strong>Conclusion: </strong>Treatment with Melphalan/HDS shows clinically meaningful efficacy and demonstrates a favorable benefit-risk profile in patients with unresectable mUM as compared to BAC.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Visual Abstract: The Effectiveness of Superparamagnetic Iron Oxide Nanoparticles in Reducing Unnecessary Sentinel Lymph Node Biopsies","authors":"Erin Kim BS,&nbsp;Lesly A. Dossett MD, MPH,&nbsp;Tasha M. Hughes MD, MPH,&nbsp;Jacqueline S. Jeruss MD, PhD,&nbsp;Michael S. Sabel MD,&nbsp;Melissa L. Pilewskie MD","doi":"10.1245/s10434-025-17220-0","DOIUrl":"10.1245/s10434-025-17220-0","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":"32 6","pages":"4063 - 4064"},"PeriodicalIF":3.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the Role of Hyperthermic Intraperitoneal Chemotherapy in Cytoreductive Surgery for Advanced-Stage Ovarian Cancer.","authors":"Adrian Kohut, Matthew L Anderson, Vaagn Andikyan, Maya Yasukawa, Lindsey Nguy, Andreas Karachristos, Timothy Nywening, Gil Mor, Radhika Gogoi, Joshua G Cohen, Jeff F Lin, Thomas J Rutherford","doi":"10.1245/s10434-025-17269-x","DOIUrl":"https://doi.org/10.1245/s10434-025-17269-x","url":null,"abstract":"<p><strong>Background: </strong>Hyperthermic intraperitoneal chemotherapy (HIPEC) is used to eliminate minimal residual disease in patients with peritoneal surface malignancies, including advanced epithelial ovarian cancer (EOC). While some trials suggest potential benefits, the role of HIPEC during cytoreductive surgery (CRS) in EOC remains uncertain. This study aimed to evaluate outcomes for patients undergoing HIPEC during CRS for advanced-stage EOC in the United States (US).</p><p><strong>Methods: </strong>This multicenter, retrospective cohort study included women with stage III-IV EOC who underwent CRS with or without HIPEC between 2006 and 2021 at Commission on Cancer-accredited US facilities. Propensity score matching was used to create a control group of patients who underwent CRS only. Overall survival (OS) was analyzed using the Kaplan-Meier log-rank method and adjusted for confounding factors with Cox proportional hazards regression.</p><p><strong>Results: </strong>Among 1400 patients identified, 700 underwent CRS with HIPEC and 700 underwent CRS only. Of these 1400 patients, 932 underwent interval CRS and 468 underwent primary CRS. No significant difference in median OS was observed between the overall CRS+HIPEC and CRS-only groups (57.6 vs. 47.6 months; p = 0.105). However, interval CRS+HIPEC was associated with significantly improved median OS compared with interval CRS-only (57.6 vs. 45.7 months; p = 0.003). After adjustment, HIPEC remained significantly associated with improved survival (hazard ratio 0.77, 95% confidence interval 0.64-0.92; p = 0.004).</p><p><strong>Conclusions: </strong>HIPEC is associated with improved OS in patients undergoing interval CRS for advanced-stage EOC. Further research should explore the selective use of HIPEC during interval CRS.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}